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Abstract  
Graves’ disease (GD) and autoimmune thyroiditis (AT) are the two main clinical presentations of 
AITD, and their clinical hallmarks are thyrotoxicosis and hypothyroidism, respectively. GD, and 
AT, can be associated with other organ specific, or systemic autoimmune diseases in the same 
patient. However discordant results have been reported in the literature about the possible 
associations. Here, we review the association of GD and other autoimmune syndromes. 
Furthermore, we report the results of our prospective study that investigated the prevalence of other 
autoimmune disorders in 3209 GD patients (984 with Graves’ ophthalmopathy), with respect to 
1069 healthy controls, or 1069 patients with AT, or 1069 with multinodular goiter (matched by age, 
gender, coming from the same area, with a similar iodine intake).  
On the whole, 16.7% of GD patients had another associated autoimmune disease; and the most 
frequently observed were: vitiligo  (2.6%), chronic autoimmune gastritis (2.4%), rheumatoid 
arthritis  (1.9%), polymyalgia rheumatica (1.3%), multiple sclerosis (0.3%), celiac disease (1.1%), 
diabetes (type 1) (0.9%), systemic lupus erythematosus and sarcoidosis (<0.1%), Sjogren disease 
(0.8%). Moreover, 1.5% patients with GD had three associated autoimmune disorders.  
Interestingly, patients with Graves’ ophthalmopathy (GO) had another autoimmmune disorder more 
frequently (18.9%), with respect to GD patients without GO (15.6%). However the pattern of the 
associated autoimmune disorders in GD was not significantly different from that observed in AT 
patients.  
In conclusion, we suggest GD patients who are still sick, or who develop new unspecific symptoms 
(even if during an appropriate treatment of hyperthyroidism) should be appropriately screened for 
the presence of other autoimmune disorders. 
 
Keywords: Autoimmune thyroid diseases, Graves’ diseases, Graves’ ophthalmopathy, 
Autoimmune thyroiditis, vitiligo, chronic autoimmune gastritis, rheumatoid arthritis, polymyalgia 
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rheumatica, celiac disease, type 1 diabetes (type 1), Sjogren disease, multiple sclerosis, systemic 
lupus erythematosus,  sarcoidosis.  
 
Take-home messages:  
• About 17% of Graves’ diseases (GD) patients had another associated autoimmune disease; 
and the most frequently observed were: vitiligo, chronic autoimmune gastritis, rheumatoid arthritis, 
polymyalgia rheumatica, multiple sclerosis, celiac disease, diabetes (type 1), systemic lupus 
erythematosus and sarcoidosis, Sjogren disease. Moreover, 1.5% patients with GD had three 
associated autoimmune disorders. Interestingly, patients with Graves’ ophthalmopathy (GO) had 
another autoimmmune disorder more frequently (18.9%), with respect to GD patients without GO 
(15.6%). 
• GD patients who are still sick, or who develop new unspecific symptoms (even if during an 
appropriate treatment of hyperthyroidism) should be appropriately screened for other autoimmune 
disorders (not to delay the diagnosis), and treatment of these ones, overall when GO is present. 
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1. Introduction 
Autoimmune thyroid diseases (AITD) are the most frequent autoimmune disorders and result from 
an immune assault on the thyroid, and they are classified as “T cell-mediated organ-specific 
autoimmune disorders” [1]. AITD include two main clinical presentations: Autoimmune thyroiditis 
(AT) and Graves’ disease (GD). The clinical hallmarks of GD and AT are thyrotoxicosis and 
hypothyroidism, respectively. The prevalence of AITD is about 5% [2]; however, the prevalence of 
antithyroid antibodies (ATA) may be even higher [3]: (1) the risk of women in comparison to men 
is more elevated (approximately 6/1); (2) hypothyroidism is more frequent in older people; (3) there 
is a great geographic variability, and the prevalences of AITD and thyroid antibodies differ with 
race; (4) the incidence of AITD is more elevated in subjects living in iodine-sufficient areas in 
comparison to those in iodine-deficient areas [3]. The incidence rate of AITD is increasing [4], even 
if it is not possible to know whether this is due to a higher accuracy of diagnostic procedures [5−8].  
In many cases, AITD may be associated in the same patient with other organ-specific autoimmune 
attacks (such as in the case of type II autoimmune polyglandular sindrome); the most frequent 
association was between AITD and type I diabetes (T1D) [9-12].  
Furthermore, ATA and thyroid function abnormalities have been frequently described in patients 
with systemic rheumatologic autoimmune diseases, such as Sjögren’s syndrome (SS), rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) [13-17]. 
Recently it has been reported a high frequency (9.67%) of coexisting autoimmune disorders in 2791 
GD patients from UK [18]. 
However other discordant results have been reported in the literature [19-22]. 
It has been suggested that, the small samples size, the use of retrospective recruitment of cases, and 
of control groups not matched by gender, age or geographic distribution, or iodine intake, could 
have hindered the data published by different papers. Furthermore, to eliminate bias in case 
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selection, prospective studies and a tight disease definition are needed [23]. 
Here, we review the association of GD and other autoimmune syndromes. Furthermore, we report 
the results obtained in our prospective study that investigated the prevalence of other autoimmune 
disorders in GD patients, with respect to healthy controls, or patients with AT, or with multinodular 
goiter. 
 
2. Material and Methods 
 
2.1 Study subjects 
From 1993 to 2010 we have evaluated prospectively the prevalence of other autoimmune disorders 
in outpatient clinic in 3209 consecutive Caucasian patients with GD (Table 1), with or without 
ophthalmopathy (GO). The diagnosis of GD [24] was established from the clinical presentation 
(presence of a diffuse goiter, varying in size from normal to very large), thyroid hormones and 
thyroid autoantibodies measurements [presence of anti-TSH-receptor autoantobodies (TRAb), 
and/or thyroid ultrasonography (decreased, dyshomogeneous echogenicity, and diffuse goiter)]. The 
majority of these patients had goiter (63%), the others showed a normal thyroid volume. A minority 
of patients (7%) were submitted to fine-needle aspiration to exclude the presence of thyroid cancer 
or lymphoma; in these cases, cytology excluded the presence of a malignancy [24, 25].  
The diagnosis of GO was established from the clinical presentation [26].  
In GO patients, eye disease activity was assessed by the Clinical Activity Score (CAS) [27]. 
2.2. Control groups 
The prevalence of autoimmune disorders was investigated in three age (±5 years), and gender, 
matched, control groups (3 patients/1 control) (Table 1), extracted from the same random sample of 
the general population, with similar iodine intake. 
Control I (n = 1069) comprised people extracted ramdonly from the general population of the same 
geographic area [28]. A complete thyroid screening [history; physical examination; 
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ultrasonography; free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone 
(TSH), anti-thyroperoxidase (AbTPO) and anti-thyroglobulin (AbTg) autoantibodies dosage] in this 
control group excluded the presence of thyroid disorders. 
Control II was constituted by 1069 patients with autoimmune thyroiditis (AT) extracted from the 
same random sample of the general population. The diagnosis of AT [14,29] was established from 
the clinical presentation (presence of a firm goiter, varying in size from small to very large, with a 
lobulated surface), thyroid hormones and thyroid autoantibodies measurements, and/or thyroid 
ultrasonography (decreased, dyshomogeneous echogenicity) [28]. 
The majority of these patients had a normal thyroid volume, some showed goiter (9%) or atrophic 
thyroiditis (10%). A minority of patients (7%) were submitted to fine-needle aspiration to exclude 
the presence of thyroid cancer or lymphoma; in these cases, cytology confirmed the presence of a 
lymphocytic infiltration [14,28].  
Control III comprised 1069 patients with non-toxic multinodular goiter (MNG) extracted from the 
same random sample of the general population. The majority of these patients had a normal thyroid 
volume, some showed goiter (35%). All MNG patients were submitted to thyroid ultrasonography 
and fine-needle aspiration, if necessary; cytology confirmed the absence of a malignancy. 
In all patients and controls, a blood sample was collected in the morning, after overnight fasting, 
and serum was kept frozen until thyroid hormones, and thyroid autoantibodies measurements. 
All study subjects gave their informed consent to the study, which was approved by the local Ethical 
Committee of the University of Pisa.  
Thyroid blood flow was evaluated using color-flow doppler in all patients, and controls [14,28].  
2.3. Laboratory tests 
Thyroidal function and autoantibodies were evaluated as earlier described [29]. Serum FT3 and FT4 
were evaluated by radio-immuno assay (RIA) (AMERLEX-MAB FT3/FT4 Kit; Amersham, UK), 
while TSH (DiaSorin, USA), AbTPO and AbTg (ICN Pharmaceuticals, USA) by IRMA. Positivity 
for AbTg or AbTPO, was defined as > 50, and >10 IU/mL, respectively. TRAb (anti-TSH-receptor 
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autoantibodies) were measured in patients with the use of a radioreceptor assay (Radim, Italy) 
(normal range 0-1 UI/ml). 
2.4. Evaluation of other autoimmune diseases 
During the study enrollment a specialist physician interviewed the patients, and a clearly defined 
questionnaire was completed by controls and patients in order to evaluate the presence of other 
frequent autoimmune disorders. The diagnosis of other autoimmune diseases was done recalling 
patients, cross-checking with present records and medications by the recruiting physician. Moreover 
a specific specialist (i.e. rheumatologist, dermatologist, gastroenterologist or internal medicine 
physician) verified the diagnoses and confirmed or not it according to the criteria reported by the 
scientific societies [30]. 
A patient was defined as “positive”, only in the presence of a clear evidence of coexisting 
autoimmune diseases. 
2.5. Data analysis  
For normally distributed variables, values are expressed as mean ± SD. For normally distributed 
variables one-way analysis of variance (ANOVA) or the Mann-Whitney U test was used to 
compare mean group values. χ2 test was used to compare proportions and Bonferroni-Dunn test for 
post-hoc comparisons on normally distributed variables. 
 
3. Results  
Table 1 reports thyroid evaluation in GD, AT, and MNG patients vs. controls. The four groups were 
not different, in gender or age distribution because of the matching procedure. Thyroid volume was 
significantly larger in GD, and MNG patients. In GD, and AT, a hypoechoeic (58%, and 64%, 
respectively) and hypervascular (64%, and 29%, respectively) thyroid was present. All GD patients 
were hyperthyroid, while 24% of AT patients were hypothyroid; no thyroid dysfunction were 
present in MNG patients and controls. In GD, and AT, AbTPO (65%, and 84%, respectively), or 
 8 
AbTg (54%, and 75%, respectively) autoantibodies were present. TRAb were present only in GD 
patients (87%). 
In GD, or AT patients a significantly  higher prevalence (Table 2) of autoimmune diseases (vs. 
controls or MNG patients) was observed for the following: T1D; celiac disease; chronic 
autoimmune gastritis (CAG); vitiligo (Vit); RA; SSc; SS; SLE; sarcoidosis; hepatitis C virus 
(HCV)-related mixed cryoglobulinemia (MC); polymyalgia rheumatica (Polym); multiple scleosis. 
For psoriatic arthritis and alopecia, a statistical evaluation closed to the significance was reported, 
while no significance was observed for the other diseases. On the whole the prevalence of another 
autoimmune disease was significantly higher in GD, or AT patients, with respect to MNG, or 
controls (16.7%, 18.5%, 3.5%, and 3.3%; respectively). The most commonly reported autoimmune 
diseases in GD patients were: Vit  (2.6%), CAG (2.4%), RA  (1.9%), Polym (1.3%), celiac disease 
(1.1%), T1D (0.9%), SS (0.8%), multiple sclerosis (0.3%), SLE and sarcoidosis (<0.1%). The 
pattern of the associated autoimmune disorders in GD was not significantly different from that 
observed in AT patients.  
The association of three autoimmune disorders was reported in 48 (1.5%) GD patients, in 15 (1.4%) 
AT patients, in only 1 control subject, and in none MNG patient (Table 3). The most common 
associations in GD were GD+CAG+Polym and GD+CAG+Vit. The pattern of the three associated 
autoimmune diseases in GD was not significantly different from that observed in AT patients. 
The presence of GO was observed in 984 (30.6%) of GD patients; while 2225 (69.4%) had no sign 
of GO. The pattern of the associated autoimmune disorders in GD, with or without GO, was not 
significantly different (Table 4). However, on the whole the prevalence of another autoimmune 
disorder was signficantly higher in GO (18.9%), than in GD patients without GO (15.6%). 
 
4. Discussion 
This is, as far as we know, the largest prospective study that have evaluated the association of other 
autoimmune diseases in patients with GD. On the whole 16.7% of GD patients had another 
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associated autoimmune disease; and the most frequently observed were: Vit  (2.6%), CAG (2.4%), 
RA (1.9%), Polym (1.3%), celiac disease (1.1%), T1D (0.9%), SS (0.8%), multiple sclerosis (0.3%), 
SLE and sarcoidosis (<0.1%). Moreover, 1.5% patients with GD had three associated autoimmune 
disorders. This study first shows that GO patients had another autoimmmune disorder more 
frequently (18.9%), with respect to GD patients without GO (15.6%). However the pattern of the 
associated autoimmune disorders in GD was not significantly different from that observed in AT 
patients. 
These results extend and complete the findings of other studies. For example the results are only in 
part in agreement with those reported recently in a cross-sectional retrospective multicenter study of 
2791 Caucasian subjects with GD in UK. All subjects completed a structured questionnaire seeking 
a personal history of common autoimmune disorder. In GD the frequency of another autoimmune 
disorder was 9.67%. RA was the most frequent coexisting autoimmune disorder (in 3.15% of GD). 
In GD relative risks of other autoimmune diseases were significantly increased (for pernicious 
anemia, SLE, Addison’s disease, celiac disease, and Vit) [18]. However, for each autoimmune 
disease the relative risk was calculated dividing the observed prevalence by the best estimate of UK 
population prevalence according to the present literature, but an appropriate internal control group 
was lacking.  
Our paper has some important strength points in comparison to the above reported paper: 1) it is a 
prospective study; 2) the definition of GD, AT, MNG, and healthy subjects has been performed by a 
complete thyroid screening; 3) a specialist (i.e. rheumatologist, dermatologist, gastroenterologist or 
internal medicine physician) verified the presence of other autoimmune diseases and confirmed or 
not it, according to criteria reported by the scientific societies (not on the basis of a questionnaire); 
4) our study reports three age- and gender-matched control groups (in fact, age and gender, are a 
determinant risk factor for thyroid autoimmunity), excluding the influence of these parameters on 
the last results; 5) the three controls were extracted from a sample of the general population, with 
similar iodine intake; 6) a control group of healthy subjects (without thyroid autoimmune disorders) 
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has permitted to emphasize the differences with GD patients; 7) a control group of MNG patients 
without thyroid autoimmunity has permitted to rule out the possible effect of non-autoimmune 
thyroid pathologies on the results; 8) a control group of AT patients has permitted to compare the 
coexistence of autoimmune diseases, with respect to GD; 9) GD patients were evaluted for the 
presence/absence of GO, making possible the comparions of the associated autoimmune diseases in 
GO, vs. GD patients without GO; 10) a larger number of patients and controls has been evaluated; 
11) a larger number of autoimmune diseases have been evaluated. 
A significant high prevalence of autoimmune disorders was reported in GD patients for: T1D; 
CAG; celiac disease; Vit; Polym; RA; SSc; SS; SLE; sarcoidosis; MC; multiple scleosis. For 
psoriatic arthritis and alopecia, a statistical evaluation closed to the significance was reported, while 
no significance was observed for the other diseases. A larger series of patients is necessary to 
confirm or not the associations for some of the other autoimmune diseases, as the statistical 
significance is difficult to be reached, owing to the low prevalence of these disorders (i.e. 
dermatomyositis, or primary biliary cirrhosis, etc). 
Of note, the association of 3 autoimmune diseases was reported nearly only in GD and AT patients, 
and the most common associations in GD were GD+CAG+Vit and GD+CAG+Polym. The pattern 
of the three associated autoimmune diseases in GD was not significantly different from that 
observed in AT patients. 
The exact pathogenetic mechanisms underlying the above reported associations are not known. The 
influence of genetic suceptibility on the association of distinct autoimmune disorders has been 
reported, as: a) significant clustering of AITD is shown within families (as about 40-50% of AT 
patients report another family member with AT) [31]; b) evidence comes from twin studies for GD 
[32] and AT [33] with concordance rates of 30–40% in monozygotic twins and 0–7% in dizygotic 
twins. Moreover, new recent insights in genome-wide association studies (GWAS) about 
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autoimmune and immune-mediated diseases have increased the knowledge of the pathogenesis 
underlying these disorders [20], suggesting a common genetic susceptibility [20,34]. 
However, also environmental factors are determinant for the appearance of AITD in susceptible 
subjects [35,36]. Increased iodine intake, selenium and vitamin D deficiency, exposure to radiation 
(from nuclear fallout, or due to medical radiation) are environmental factors increasing AITD 
prevalence [37].  
Cigarette smoking is associated with GD and GO, while it decreases the risk of hypothyroidism and 
thyroid autoimmunity. Viral infections are important environmental factors in the pathogenesis of 
AITD, too, particularly human parvovirus B19 (EVB19) and HCV. Regarding the various existing 
chemical contaminants, pesticides and halogenated organochlorines differently disrupt thyroid 
function. Polychlorinated biphenyls and their metabolites and polybrominated diethyl ethers bind to 
thyroid transport proteins (i.e. transthyretin), displace thyroxine, and disrupt thyroid function. 
Considering drugs, interferon- and iodine-containing drugs have been associated with AITD [35].  
A prevalent Th1 immune pattern has been shown in patients with AT, GD, GO [38-40], T1D, SLE, 
SSc, RA, MC, and others, in the initial phase of these disorders. Furthermore, in GD, GO, SLE, MC 
(and others) a Th1 prevalence has been shown in the active phase, that switches to a Th2 profile in 
the inactive phase [28, 29, 38, 41-43] of the disease. So it has been hypothesized that the influence 
of genetic and environmental factors could determinate autoimmune phenomena in different organs 
in the same subject [1], characterized by predominance of a Th1 immune pattern at the initial, or 
active, phase of these disorders.  
In conclusion, it has been demonstrated a significantly more elevated risk of other autoimmune 
diseases in GD patients. Since about 17% of GD patients can have another associated autoimmune 
disease, GD patients who are still sick, or who develop new unspecific symptoms (even if during an 
appropriate treatment of hyperthyroidism) should be appropriately screened for other autoimmune 
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disorders (not to delay the diagnosis), and treatment of these ones, overall when GO is present. 
 13 
Funding: 
This research did not receive any specific grant from funding agencies in the public, commercial, or 
not-for-profit sectors. 
 
 
 
 14 
References 
 
1)  Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid 
disorders. Autoimmun Rev 2015;14:174–80.  
2) Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The 
incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham 
Survey. Clinical Endocrinol (Oxford) 1995;43:55–68. 
3)  McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity Endocrine 
2012;2:252–65.  
4) Pedersen IB, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, et al. An increased 
incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a 
prospective population study. J Clin Endocrinol Metab 2007;92:3122–7. 
5) Rizzo M, Rossi RT, Bonaffini O, Scisca C, Altavilla G, Calbo L, et al. Increased annual 
frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of 
Sicily. Ann Endocrinol (Paris) 2010;71:525–34. 
6) Benvenga S1, Trimarchi F, Robbins J. Circulating thyroid hormone autoantibodies. J 
Endocrinol Invest 1987;10:605–19. 
7) Latina A, Gullo D, Trimarchi F, Benvenga S. Hashimoto's thyroiditis: similar and dissimilar 
characteristics in neighboring areas. Possible implications for the epidemiology of thyroid 
cancer PloS One 2013;8:e55450. 
8) Rizzo M, Sindoni A, Talamo Rossi R, Bonaffini O, Panetta S, Scisca C, et al. Annual 
increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle 
aspiration at a cytology unit in Sicily. Hormones (Athens) 2013;12:46–57. 
9) Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-
term follow-up. J Clin Endocrinol Metab 2003;88:2983–92. 
 15 
10) Antonelli A, Tuomi T, Nannipieri M, Fallahi P, Nesti C, Okamoto H, et al. Autoimmunity 
to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical 
phenotypes. Diabetologia 2002;45:1298–306. 
11) Trimarchi F, De Luca F, Vanelli M, Benvenga S, Siracusano MF, Volta C, et al. Circulating 
thyroid antibodies and thyroid function studies in children and adolescents with insulin-
dependent diabetes mellitus. Eur J Pediatr 1984;142:253–6. 
12) Pupilli C, Giannini S, Marchetti P, Lupi R, Antonelli A, Malavasi F, et al. Autoantibodies 
to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with 
diabetes: effects on insulin release from human islets. Diabetes 1999;48:2309-15. 
13)  Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R, et al. The association of other 
autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and 
report of a large series of  patients. Autoimmun Rev 2016;15:1125–8. 
14) Antonelli A, Fallahi P, Mosca M, Ferrari SM, Ruffilli I, Corti A, et al. Prevalence of 
thyroid dysfunctions in systemic lupus erythematosus. Metabolism 2010;59:896–900. 
15) Antonelli A, Mosca M, Fallahi P, Neri R, Ferrari SM, D'Ascanio, et al. Thyroid cancer in 
systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2010;95:314–
8. 
16) Han TY, Lee JH, Noh TK, Choi MW, Yun JS, Lee KH, et al. Alopecia areata and overt 
thyroid diseases: A nationwide population-based study. J Dermatol 2018;45:1411-1417. 
17) Nisihara R, Pigosso YG, Prado N, Utiyama SRR, De Carvalho GA, Skare TL. Rheumatic 
Disease Autoantibodies in Patients with Autoimmune Thyroid Diseases. Med Princ Pract 
2018;27:332-336. 
18) Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. 
Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune 
thyroid disease. Am J Med. 2010;123:183.e1–9. 
 16 
19)  Miyadera H, Tokunaga K. Associations of human leukocyte antigens with autoimmune 
diseases: challenges in identifying the mechanism. J Hum Genet 2015;60:697–702. 
20) Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights 
from genetics and implications for new therapies. Nat Med 2015;21:730–8. 
21) Robazzi TC, Adan LF. Autoimmune thyroid disease in patients with rheumatic diseases. 
Rev Bras Reumatol 2012;52:417–30. 
22) Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 
2003;2:119–25. 
23) Jenkins RC, Weetman AP. Disease associations with autoimmune thyroid disease. Thyroid 
2002;12:977–88.  
24) Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, et al. Anti-CD38 
autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp 
Immunol. 2001;126:426–31. 
25) Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L. Completion total 
thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch 
Surg 1998;133:89–93.  
26) Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, et al. Intravenous 
immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 
1997;7:579–85.  
27) Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. 
Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel 
approach. Brit J Ophthalmol 1989;73:639–644. 
28) Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. 
High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic 
arthtritis. Clin Exp Rheumatol 2009;27:22–7.  
 17 
29) Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, et al. High values of 
CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in 
presence or absence of autoimmune thyroiditis. Cytokine 2008;42:137–43. 
30) Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune 
diseases: improved prevalence estimates and understanding of clustering of diseases. J 
Autoimmun 2009;33:197–207. 
31) Brix TH, Christensen K, Holm NV, Harvald B, Hegedus L. A population-based study of 
Graves' disease in Danish twins. Clin Endocrinol (Oxf) 1998;48:397–400. 
32) Ringold DA, Nicoloff JT, Kesler M, Davis H, Hamilton A, Mack T. Further evidence for a 
strong genetic influence on the development of autoimmune thyroid disease: the California 
twin study. Thyroid 2002;12:647–53. 
33) Brix TH, Kyvik KO, Hegedus L. A population-based study of chronic autoimmune 
hypothyroidism in Danish twins. J Clin Endocrinol Metab 2000;85:536–9. 
34) Su H, Rei N, Zhang L, Cheng J. Meta-analyses of IL1A polymorphisms and the risk of 
several autoimmune diseases published in databases. PLoS One 2018;13:e0198693. 
35) Ferrari SM, Fallahi P, Antonelli A, Benvenga S. Environmental Issues in Thyroid Diseases. 
Front Endocrinol (Lausanne) 2017;8:50. 
36) Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, 
Cantarini L, Bogdanos DP, Antonelli A, Amital H, Valesini G, Shoenfeld Y. Smoke and 
autoimmunity: The fire behind the disease. Autoimmun Rev. 2016;15:354-74. 
37) Martino E, Macchia E, Aghini-Lombardi F, Antonelli A, Lenziardi M, Concetti R, et al. Is 
humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis 
(AIIT)? Clin Endocrinol (Oxf) 1986;24:627–33. 
38) Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, et al. CXCL9 and 
CXCL11 chemokines modulation by peroxisome proliferator-activated receptoralpha 
 18 
agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 2010;95:413–
20. 
39) Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10 and type 1 
diabetes. Cytokine Growth Factor Rev 2014;25:57–65.  
40) Zhao J, Lin B, Deng H, Zhi X, Li Y, Liu Y, Bible PW, Li Q, Xu B, Wei L, Yang H, Huang 
D. Decreased Expression of TIM-3 on Th17 Cells Associated with Ophthalmopathy in 
Patients with Graves' Disease. Curr Mol Med. 2018;18:83-90. 
41) Zignego AL. Enhanced TH1 cytokine production in hepatitis C virus-infected patients with 
mixed cryoglobulinemia: understanding the pathological issues. J Hepatol 2004;41:1045–9. 
42) Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C 
motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014;13(3):272–80. 
43) Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-
related disorders. Clin Dev Immunol. 2012;2012:468107. 
 19 
Table 1. Thyroid status of control subjects, and patients with autoimmune thyroiditis, or euthyroid 
multinodular goiter, or Graves' disease. 
 
 controls I thyroiditis multinodular Graves' P 
     goiter disease   
n 1069 1069 1069 3209  
      
Age (years) 44 ± 16 45 ± 17 46 ± 9 44 ± 15 ns 
      
Gender (M/F)% 18 18 18 18 ns 
      
Thyroid volume (ml) 10 ± 6 13 ± 10 19 ± 18* 21±16* 0.0001 
      
Hypoechoic (%) 0 64 0 58 0.0001 
      
Hypervascular (%) 0 29 0 64 0.0001 
      
Serum TSH (mcU/ml) 1.5 ± 0.9 2.8± 3.0 1.2 ± 0.8 0.1 ± 0.2§ 0.001 
      
TRAb  positivity (%) 0 0 0 87§ 0.0001 
      
AbTPO positivity (%) 0 84 0 65 0.0001 
      
AbTg positivity (%) 0 75 0 54 0.0001 
      
            
Antithyroperoxidase antibody = AbTPO     
Antithyroglobulin antibody = AbTg      
Thyroid-stimulating hormone = TSH     
Antithyrotropin-receptor antibody=TRAb     
* p <0.05 or less vs. controls or vs. autoimmune thyroiditis 
§ p<0.05 or less vs. controls, vs. autoimumune thyroiditis and vs. multinodular goiters 
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Table 2.  Distribution of autoimmune diseases in GD patients, controls, AT, and MNG. 
 Controls 
n = 1069 
AT 
n = 1069 
MNG 
n = 1069 
GD 
n = 3209 
P 
χ2 
Diabetes (type 1)  1 10 0 28 0.0008 
Addison disease 0 2 0 4 0.3427 
Chronic autoimmune gastritis 5 27 10 78 <0.0001 
Celiac disease 3 14 4 34 0.0105 
Crohn disease 0 3 2 10 0.3157 
Ulcerative colitis 2 6 1 13 0.2070 
Vitiligo   6 29 3 83 < 0.0001 
Alopecia 0 4 0 9 0.0765 
Psoriasis 3 5 3 16 0.6772 
Psoriatic arthritis 1 6 0 11 0.0503 
Myasthenia gravis 0 1 0 4 0.4574 
Polymyalgia rheumatica 5 14 6 41 0.0388 
Polymyositisy/dermatomyositis  0 2 0 7 0.2071 
Primary biliary cirrhosis 0 1 0 2 0.6442 
Chronic autoimmune hepatitis 0 1 0 2 0.6442 
Rheumatoid arthritis   5 26 4 64 < 0.0001 
Systemic sclerosis (scleroderma)  0 6 0 15 0.0132 
Sjogren disease 1 10 0 27 0.0009 
Systemic lupus erythematosus 0 8 0 21 0.0021 
Sarcoidosis 1 7 0 17 0.0173 
HCV-related cryoglobulinemia 0 6 0 14 0.0153 
Glomerulonephritis Primary  IgA 0 0 0 1 0.8014 
Multiple sclerosis  2 7 2 26 0.0409 
 Uveitis (iridocyclitis) 1 3 3 10 0.6885 
Total 36 
(3.3%) 
 198 
(18.5%) 
38 
(3.5%) 
536  
(16.7%) 
<0.0001 
P>0.05 AT, vs. GD, for all comparisons 
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Table 3. Patients with 3 associated autoimmune disorders in GD patients, controls, AT, and MNG. 
 Controls 
n = 1069 
AT 
n = 1069 
MNG 
n = 1069 
GD 
n = 3209 
P 
χ2 
AT+CAG+Vit 1 4 0 13 ns 
AT+CAG+Polym 0 2 0 7 ns 
AT+CAG+Alo 0 1 0 3 ns 
AT+CAG+T1D 0 0 0 2 ns 
AT+CAG+SLE 0 1 0 2 ns 
AT+CAG+Sarc 0 1 0 1 ns 
AT+CAG+SSc 0 0 0 1 ns 
AT+CAG+Sjog 0 1 0 4 ns 
AT+Vit+Sjog 0 1 0 3 ns 
AT+Vit+Polym 0 1 0 4 ns 
AT+T1D+CelDis 0 1 0 3 ns 
AT+RA+Vit 0 1 0 2 ns 
AT+Sarc+Vit 0 0 0 1 ns 
AT+Crohn+Vit 0 0 0 1 ns 
AT+Sarc+Vit 0 1 0 1 ns 
Total 1 15 0 48 < 0.0001 
Alopecia (Alo); autoimmune thyroiditis (AT); celiac disease (CelDis); chronic autoimmune gastritis 
(CAG); Crohn disease (Crohn); polymyalgia rheumatica (Polym); rheumatoid arthritis (RA); 
sarcoidosis (Sarc); sjögren’s syndrome (Sjog); systemic lupus erythematosus (SLE); systemic 
sclerosis (SSc); type 1 diabetes (T1D); ulcerative colitis (UlcCol); vitiligo (Vit). 
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Table 4.  Distribution of autoimmune diseases in GD patients, with or without GO. 
 No GO 
n = 2225 
With GO 
n = 984 
(30.6%) 
GD 
n = 3209 
P 
χ2 
Diabetes (type 1)  18 10 28 ns 
Addison disease 3 1 4 ns 
Chronic autoimmune gastritis 51 27 78 ns 
Celiac disease 21 13 34 ns 
Crohn disease 6 4 10 ns 
Ulcerative colitis 9 4 13 ns 
Vitiligo   50 33 83 ns 
Alopecia 5 4 9 ns 
Psoriasis 11 5 16 ns 
Psoriatic arthritis 8 3 11 ns 
Myasthenia gravis 3 1 4 ns 
Polymyalgia rheumatica 28 13 41 ns 
Polymyositisy/dermatomyositis  5 2 7 ns 
Primary biliary cirrhosis 2 0 2 ns 
Chronic autoimmune hepatitis 1 1 2 ns 
Rheumatoid arthritis   40 24 64 ns 
Systemic sclerosis (scleroderma)  10 5 15 ns 
Sjogren disease 17 10 27 ns 
Systemic lupus erythematosus 15 6 21 ns 
Sarcoidosis 13 4 17 ns 
HCV-related cryoglobulinemia 10 4 14 ns 
Glomerulonephritis Primary  IgA 1 0 1 ns 
Multiple sclerosis  17 7 25 ns 
 Uveitis (iridocyclitis) 5 5 10 ns 
Total  349 
(15.6%) 
187 
(18.9%) 
 536 
(16.7%) 
0.0201 
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Highlights 
 
• About 17% of GD patients had another associated autoimmune disease 
• The association of 3 autoimmune diseases is present in 1.5 % of GD patients 
• GO patients had another autoimmmune disorder more frequently vs. GD without GO  
• The pattern of associated autoimmune disorders in GD is not different than in AT  
• GD developing new unspecific symptoms should be screened for autoimmune disorders 
 
